CL2017003017A1 - Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer - Google Patents
Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancerInfo
- Publication number
- CL2017003017A1 CL2017003017A1 CL2017003017A CL2017003017A CL2017003017A1 CL 2017003017 A1 CL2017003017 A1 CL 2017003017A1 CL 2017003017 A CL2017003017 A CL 2017003017A CL 2017003017 A CL2017003017 A CL 2017003017A CL 2017003017 A1 CL2017003017 A1 CL 2017003017A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- intratumoral injection
- immune response
- tumor development
- cancer
- Prior art date
Links
- 229920001661 Chitosan Polymers 0.000 title abstract 3
- 238000002347 injection Methods 0.000 title abstract 3
- 239000007924 injection Substances 0.000 title abstract 3
- 230000002601 intratumoral effect Effects 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000005748 tumor development Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 241001516406 Avian orthoreovirus Species 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>La presente invención se relaciona con el área farmacéutica, y especialmente, con una composición farmacéutica para inyección intratumoral que comprende nanopartículas de origen natural (quitosano) que se usan como vectores para la encapsulación de genes de proteínas que son capaces de controlar el desarrollo tumoral, crear respuesta inmune o ambos. En particular, la composición farmacéutica para inyección intratumoral comprende nanopartículas de quitosano que encapsula ADN de la proteína de fusión de Reovirus Aviar (REO), la que retrasa el crecimiento tumoral y eventualmente conduce a su eliminación vía generación de sincicios, y su uso en el tratamiento del cáncer por transfección in vivo. </p>The present invention relates to the pharmaceutical area, and especially, to a pharmaceutical composition for intratumoral injection comprising naturally occurring nanoparticles (chitosan) that are used as vectors for encapsulation of protein genes that are capable of controlling the tumor development, create immune response or both. In particular, the pharmaceutical composition for intratumoral injection comprises chitosan nanoparticles that encapsulates DNA from the Avian Reovirus fusion protein (REO), which slows tumor growth and eventually leads to its elimination via syncytial generation, and its use in the In vivo transfection cancer treatment. </p>
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2017003017A CL2017003017A1 (en) | 2017-11-28 | 2017-11-28 | Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer |
| PCT/CL2018/050115 WO2019104449A1 (en) | 2017-11-28 | 2018-11-27 | Composition for intratumoral injection comprising a dna vector encapsulated in chitosan nanoparticles and use thereof in cancer treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2017003017A CL2017003017A1 (en) | 2017-11-28 | 2017-11-28 | Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017003017A1 true CL2017003017A1 (en) | 2018-05-04 |
Family
ID=63046540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017003017A CL2017003017A1 (en) | 2017-11-28 | 2017-11-28 | Pharmaceutical composition for intratumoral injection comprising chitosan nanoparticles that encapsulates DNA of a protein capable of controlling tumor development, creating immune response or both, and its use in the treatment of cancer |
Country Status (2)
| Country | Link |
|---|---|
| CL (1) | CL2017003017A1 (en) |
| WO (1) | WO2019104449A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020187543A1 (en) * | 2001-04-05 | 2002-12-12 | Curiel David T. | Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins |
| US20140350087A9 (en) * | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
| WO2014089029A1 (en) * | 2012-12-03 | 2014-06-12 | Ohio State Innovation Foundation | Activation of innate immunity by mirna for cancer and infection treatment |
-
2017
- 2017-11-28 CL CL2017003017A patent/CL2017003017A1/en unknown
-
2018
- 2018-11-27 WO PCT/CL2018/050115 patent/WO2019104449A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019104449A1 (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15025845A (en) | ANTI-CEACAM5 ANTIBODIES AND USES OF THEM | |
| CY1123355T1 (en) | ANTIBODIES TO CD73 AND USES THEREOF | |
| CY1123138T1 (en) | CYTOTOXIC PROTEINS CONTAINING CELL-TARGETING BINDING REGIONS AND SHIGA TOXIN A SUBUNIT REGIONS FOR SELECTIVE KILL OF SPECIFIC CELL TYPES | |
| EA201690868A1 (en) | PERSONALIZED IMMUNOTHERAPY OF SEVERAL TYPES OF NEURAL TUMORS AND TUMORS OF THE BRAIN | |
| CO2017001023A2 (en) | Antibody-Carrier Compositions and Methods for Making and Using Them | |
| MX2023002858A (en) | Predicting t cell epitopes useful for vaccination. | |
| PE20181365A1 (en) | SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND THEIR USES | |
| MX359449B (en) | Anti-cd70 antibody drug conjugates. | |
| CR20180174A (en) | NEW PEPTIDES, COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER | |
| BR112017007765A2 (en) | adenosine deaminase-2 (ada2) compositions, variants thereof and methods of using it | |
| CR20180027A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN THE SAME THERAPY AGAINST OVARY EPITELIAL CANCER AND OTHER TYPES OF CANCER. | |
| MX2017017079A (en) | Cellular targeted active ingredient delivery system. | |
| EA202090751A2 (en) | A NEW METHOD OF IMMUNOTHERAPY OF SEVERAL KINDS OF TUMOR BLOOD DISEASES SUCH AS Acute Myeloid Leukemia (AML) | |
| MX2016011821A (en) | Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions. | |
| MX2018002524A (en) | Pharmaceutical composition containing, as active ingredient, fusion protein in which tumor-penetrating peptide and anti-angiogenesis agent are fused, for preventing and treating cancer or angiogenesis-related diseases. | |
| MX2020010701A (en) | ANTIGENIC PEPTIDES FOR THE PREVENTION AND TREATMENT OF CANCER. | |
| CY1122968T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT | |
| AR080313A1 (en) | COMPOSITIONS OF RECOMBINANT CANINE MACHINE VIRUS (CDV) AND ITS USES | |
| EA201991702A1 (en) | SELF-ASSEMBLY PROTEIN NANOPARTICLES INCAPSULATING IMMUNITIES MULATING NUCLEIC ACIDS | |
| HK1211874A1 (en) | High pressure apparatus and method for preparing inactivated vaccines and for refolding/solubilizing recombinant proteins | |
| MX2016014826A (en) | Curcumin-peptide conjugates and formulations thereof. | |
| EA202090319A1 (en) | PEPTIDE CONJUGATES, CONJUGATION METHOD AND THEIR USE | |
| MA37749A1 (en) | Vaccines against bluetongue and African horse sickness virus | |
| JO3565B1 (en) | Angiopoietin-like 4 antibodies and methods of use | |
| AR100745A1 (en) | QUITOSANE NANOPARTICLES LOADED WITH ANTIGEN FOR IMMUNOTHERAPY |